Meibomian Gland Expression & Meibum Quality

The meibomian glands are long glands located inside the eyelids. They produce meibum, a complex mixture of lipids that travels through ducts and exits through tiny openings along the lid margin. From there, meibum contributes to the lipid-rich outer region of the tear film.

But simply seeing glands on an image does not tell us whether they are functioning normally. Diagnostic expression asks two particularly important questions: can meibum be expressed from the glands, and what is the expressed meibum like?

These are usually described as expressibility and meibum quality.

Expressibility describes how readily the glands release their secretion when pressure is applied. A clinician may evaluate how many glands produce meibum under controlled pressure.

If many glands release secretion relatively easily, expressibility is better. If only a few produce secretion — or none do — expressibility is reduced. This can be an important sign of meibomian gland dysfunction.

But there is an important word in that description: pressure.

Meibomian gland expression is not simply a yes-or-no test. What comes out depends partly on how the examination is performed. The amount of pressure matters. The location of the pressure matters. Which glands are tested matters.

A gland that releases meibum under relatively gentle, controlled pressure is not behaving in the same way as a gland that produces material only when much stronger pressure is applied.

This is why standardized diagnostic expression is valuable. Devices have even been developed to apply controlled pressure intended to approximate the forces the eyelid normally generates during blinking. Without some consistency in technique, it becomes much harder to compare findings between examinations.

The clinician also examines the material that comes out. Healthy meibum is generally a clear fluid. With abnormal gland function, the secretion may become:

• •cloudy
• •cloudy with particles
• •thick and toothpaste-like

Clinical grading systems use these visible differences to describe meibum quality. You do not need to memorize the grades. The important point is simply: the secretion itself can change.

Not necessarily. These terms describe different things.

Meibum quality describes what the secretion is like. Expressibility describes how readily it can be obtained. Obstruction describes interference with the normal pathway through which meibum travels toward the gland opening.

They often occur together in MGD, but they are not synonyms. For example, a gland may contain abnormal thick secretion and also be difficult to express. But seeing thick meibum alone does not tell us everything happening inside that gland.

This is one of the most important parts of understanding the test.

If no visible meibum appears during expression, the finding tells us: meibum could not be expressed from those glands under the conditions of that examination.

That is meaningful. But it does not automatically mean that the gland is empty, that the gland produces no meibum, that the gland is permanently non-functional, or that the gland is “dead.”

Expression cannot directly show us what is happening throughout the inside of the gland. Poor or absent expressibility can occur in different situations. The gland opening or duct may be obstructed. The secretion may be very difficult to express. Secretory function may be reduced. Structural gland changes may be present. And the testing technique itself — including pressure and which glands were examined — can influence what is observed.

Expression alone cannot distinguish all of these possibilities.

Yes. Meibomian gland expression is a functional examination performed under particular conditions, not a permanent label attached to each gland.

Different areas of the eyelid may behave differently. The amount of pressure may differ. The secretion itself may not have identical properties at every examination. And different clinicians or devices may not perform expression in exactly the same way.

This does not make the test useless. It means that the result needs context. A repeated, standardized finding is generally more informative than an isolated observation made once.

No. That conclusion goes beyond what the test has actually shown. The accurate conclusion is narrower: little or no meibum was expressible during that examination. The next question is why. To answer that, we may need other information. For example:

• •What do the gland openings look like?
• •Is there visible obstruction at the lid margin?
• •What is the quality of secretion from glands that do express?
• •What does meibography show?
• •How many glands were tested?
• •Do repeated examinations show the same pattern?
• •And what is happening in the tear film itself?

This is a good example of a principle that applies throughout dry-eye diagnosis: a finding is not always the same thing as an explanation.

This distinction is particularly important.

Meibomian gland expression asks: what are the glands doing? Can secretion be obtained? How readily? From how many glands? And what does the secretion look like?

Meibography asks: what do the glands look like structurally? Are they present? Are they shortened? Is there visible gland loss or other structural alteration?

In simple terms: expression mainly assesses function, while meibography mainly assesses structure. Neither tells the whole story by itself.

Meibography: what gland images can — and can't — tell you

Yes. Seeing gland tissue on an image does not prove that the gland is producing and delivering normal meibum. Structure and function are related, but they are not identical.

That is why a clinician may find relatively preserved glands on meibography but abnormal expression. The reverse problem also matters: structural abnormalities on meibography do not automatically tell us exactly how much useful secretion a gland can currently deliver.

Abnormal meibum quality and reduced expressibility are important clinical findings when evaluating meibomian gland dysfunction. But MGD assessment involves more than one observation. A clinician may also consider:

• •the gland openings
• •lid-margin changes
• •obstruction
• •meibography
• •blink function
• •the effect of gland dysfunction on the tear film

Expression is therefore an important part of the assessment — but not the entire diagnosis.

Not necessarily. This is another important distinction. MGD and dry eye disease are closely related, but they are not identical.

A person may have signs of meibomian gland dysfunction without necessarily meeting the diagnostic criteria for dry eye disease. And someone can have dry eye in which meibomian gland dysfunction is not the main driver.

So abnormal gland expression is not a dry-eye diagnosis. It helps identify a possible contributor to the tear-film problem.

Not necessarily. Clear secretion is generally a favorable finding when assessing meibum quality. But quality is only one part of gland function. We also need to know how many glands are producing it, how easily it comes out, whether enough meibum is reaching the lid margin, and what the glands and lid margin look like overall.

Clear secretion from one gland does not tell us that the entire meibomian gland system is functioning normally.

Not by itself. Thick, toothpaste-like secretion is clearly abnormal and is recognized in clinical meibum-quality grading. But MGD severity is more complex than the appearance of the secretion alone. A fuller assessment may include meibum quality, expressibility, the number of functioning glands, lid-margin abnormalities, gland structure, and the effect on the tear film and ocular surface.

So toothpaste-like meibum is an important finding. It is not a complete description of the disease.

No. They may look similar, but their purposes are different.

Diagnostic expression is performed to assess gland function. The clinician wants to know what can be expressed under controlled conditions and what the secretion looks like.

Therapeutic expression is performed as a treatment, with the intention of evacuating gland contents. The pressure, technique and goal may therefore be different.

This distinction matters when interpreting what happened during an examination or treatment session.

Not completely. Meibum is the major source of lipids at the tear-film surface. So abnormal gland secretion can certainly contribute to abnormalities in the lipid component of the tear film.

But gland secretion and final tear-film behaviour are not exactly the same thing. After meibum reaches the lid margin, it still needs to be distributed across the ocular surface and incorporated into a functioning tear film. Blinking matters. The ocular surface matters. Other tear-film components matter.

So normal-looking expressed meibum does not automatically prove normal tear-film lipid function.

It can help us understand whether meibum can be expressed, how readily it comes out, how many tested glands produce secretion, and what that secretion looks like. This gives us valuable information about meibomian gland function.

Expression alone cannot tell you:

• •exactly what is happening inside a gland
• •whether a non-expressing gland is empty or permanently non-functional
• •why expressibility is reduced
• •what the entire gland looks like structurally
• •whether the tear-film lipid component is functioning normally
• •whether you have dry eye disease

Those conclusions require other information.